Windlas Biotech Limited

Equities

WINDLAS

INE0H5O01029

Pharmaceuticals

Market Closed - NSE India S.E. 08:01:54 18/05/2024 BST 5-day change 1st Jan Change
553.1 INR +1.90% Intraday chart for Windlas Biotech Limited +7.65% +29.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Windlas Biotech Commissions New Injectible Manufacturing Unit MT
Windlas Biotech Limited Commissions Its Injectable Facility CI
Windlas Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Windlas Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Windlas Biotech Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Windlas Biotech Limited Approves Final Dividend for the Financial Year 2022-23 CI
Windlas Biotech Limited Proposes Final Dividend for the Financial Year 2022-23 CI
Windlas Biotech Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Windlas Biotech's Consolidated Profit Slips in Fiscal Q4 MT
Windlas Biotech Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Windlas Biotech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Windlas Biotech Limited Recommends Dividend CI
Tranche Update on Windlas Biotech Limited's Equity Buyback Plan announced on November 8, 2022. CI
Tranche Update on Windlas Biotech Limited's Equity Buyback Plan announced on November 8, 2022. CI
Windlas Biotech Limited's Equity Buyback announced on November 8, 2022 has closed with 867,747 shares, representing 3.98% for INR 217.97 million. CI
Windlas Biotech's Consolidated Profit Climbs in Fiscal Q3 MT
Windlas Biotech Limited Appoints Komal Gupta as the Chief Executive Officer CI
Windlas Biotech Appoints CEO MT
Windlas Biotech Names New CEO MT
Windlas Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Tranche Update on Windlas Biotech Limited's Equity Buyback Plan announced on November 8, 2022. CI
Chart Windlas Biotech Limited
More charts
Windlas Biotech Limited is an India-based company that is primarily engaged in the manufacturing and trading of pharmaceutical products. The Company provides a range of contract development and manufacturing organization (CDMO) services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics. Its therapeutic categories, such as, anti-diabetic, cardiovascular, neuropsychiatry and respiratory therapies. The Company’s service capabilities include formulation development, technology scale-up and full-scale commercial manufacturing. It has capabilities for both solid and liquid pharmaceutical dosage forms. The Company markets its own manufactured nutraceutical, pharmaceutical and ayurvedic products to serve the semi-urban and rural communities. It also has a salesforce and distribution network spread across over 14 states. The Company’s manufacturing facilities are located at Dehradun in Uttarakhand.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. WINDLAS Stock
  4. News Windlas Biotech Limited
  5. Windlas Biotech's Consolidated Profit Slips in Fiscal Q4